More FDA inspection troubles for Hospira

June 7, 2013 by Sony Salzman

The FDA says Hospira’s India facility is still rife with significant violations of good manufacturing practice regulations.

Hospira (NYSE:HSP) heard from the FDA's inspection office this week with another warning that the infusion device company's India facility still contains significant violations of good manufacturing practice regulations.

The FDA originally inspected the Industrial Park, Irungattukottai, Sriperumburdur, India facility in October 2012 and found serious problem with workplace sanitation, product sterility and processing violations that meant the products coming out of that plant were considered adulterated under law.

Sign up to get our free newsletters delivered right to your inbox.

Inspectors were not satisfied with Hospira's attempt to correct the problem, and sent another warning letter late last month. Hospira officials now have to send the FDA a clean-up plan within 30 days or the agency might ban imports or refuse all new device review applications, according to an agency warning.

The FDA also expressed concerns that manufacturing problems could lead to drug shortages, and instructed the company to contact the Drug Shortage Program immediately so that "we can work with you on the most effective way to bring your operations in compliance with the law," according to the letter.